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Pancreatic ductal adenocarcinoma (PDAC) carries a
dismal prognosis and lacks a human cell model
of early disease progression. When human PDAC
cells are injected into immunodeficient mice, they
generate advanced-stage cancer. We hypothesized
that if human PDAC cells were converted to plurip-
otency and then allowed to differentiate back into
pancreatic tissue, they might undergo early stages
of cancer. Although most induced pluripotent stem
cell (iPSC) lines were not of the expected cancer
genotype, one PDAC line, 10–22 cells, when in-
jected into immunodeficient mice, generated
pancreatic intraepithelial neoplasia (PanIN) precur-
sors to PDAC that progressed to the invasive
stage. The PanIN-like cells secrete or release
proteins from many genes that are known to be ex-
pressed in human pancreatic cancer progression
and that predicted an HNF4a network in intermedi-
ate-stage lesions. Thus, rare events allow iPSC
technology to provide a live human cell model of
early pancreatic cancer and insights into disease
progression.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) carries a dismal
prognosis, with less than a 5% survival rate (Hezel et al., 2006;
Maitra and Hruban, 2008; Rustgi, 2006). Due to a paucity of bio-2088 Cell Reports 3, 2088–2099, June 27, 2013 ª2013 The Authorsmarkers for early-stage detection of the disease, PDAC is usually
detected at advanced stages, with limited therapeutic options.
Given the frequent occurrence of KRAS mutations in human
PDAC, the prominent animal model of PDAC is based upon
inducing a G12D mutant allele of Kras in the mouse pancreatic
epithelium (Hingorani et al., 2003). The mice develop pancreatic
intraepithelial neoplasias (PanINs) with prolonged latency and
incomplete penetrance of PDAC. PDAC and related tumors
develop muchmore rapidly when KrasG12D/+mice also contain
mutations of Ink4a/Arf, Tgfbr2, p53, or PTEN (Morris et al., 2010),
although thesemutations alone do not efficiently cause PDAC. In
an effort to develop human models of early pancreatic cancer,
PDAC cells have been grafted into immunodeficient mice either
as tumor fragments (Rubio-Viqueira et al., 2006), dispersed cells
(Kim et al., 2009), or cells sorted for cancer stem cell markers
(Hermann et al., 2007; Ishizawa et al., 2010; Li et al., 2007). In
these contexts, tumors rapidly arise that resemble the advanced
PDAC stages from which the cells were derived and do not
undergo the slow growing, early PanIN stages of PDAC (Ding
et al., 2010). Presently, there is no dynamic, live human cellular
model that undergoes the early stages of PDAC and disease
progression.
Most of the secreted proteins from pancreatic cancers (Har-
sha et al., 2009) that could serve as biomarkers have been iden-
tified in advanced, invasive PDAC or cell lines thereof and thus
may not represent markers for early stages of the disease.
Markers have been sought for precancerous lesions, such as
PanINs and intraductal papillary mucinous neoplasms (IPMNs)
(Brat et al., 1998; Hruban et al., 2001), but the markers are typi-
cally intracellular or cell surface proteins (Harsha et al., 2009) and
not known to be secreted or released proteins that would pro-
vide the best opportunity for diagnosis.
Although irreversible mutations in oncogenic and tumor sup-
pressor genes promote human cancers, potentially reversible
epigenetic changes also play a role (Esteller, 2007). Indeed,
the cancer phenotype can be suppressed in certain medullo-
blastoma cells, RAS-induced melanoma cells, and embryonal
carcinoma cells and renal tumor cells when they are reprog-
rammed to pluripotency by nuclear transfer (Blelloch et al.,
2004; Hochedlinger et al., 2004; Li et al., 2003; McKinnell
et al., 1969). More significantly, the resultant pluripotent cells
can then differentiate into multiple early developmental cell
types of the embryo. Such embryos die partly through organo-
genesis, presumably due to re-expression of the cancer pheno-
type. Still, it is remarkable that, in certain circumstances, the
pluripotency network can suppress the cancer phenotype suffi-
ciently to allow early tissue differentiation. Using iPSC technol-
ogy (Takahashi and Yamanaka, 2006), cancer cell lines have
been made into iPSCs (Carette et al., 2010; Miyoshi et al.,
2010). However, no iPSC lines from solid primary human can-
cers have been reported.
Based on the above considerations, we hypothesized that
creating iPSCs from an epithelial tumor would allow the cells
to be propagated indefinitely in the pluripotent state and that,
upon differentiation, a subset of the cells would undergo early
developmental stages of the human cancer. This could provide
a live cell human model for unprecedented experimental
access to early stages of the disease. We therefore sought to
reprogram epithelial cells from human PDAC, along with appar-
ently normal, isogenic cells beyond the tumor margins and
assess the reprogrammed cells’ developmental potential.
From a variety of initial PDAC samples, only once were we
able to reprogram a cell from a recurrent, late-stage human
pancreatic cancer to a near-pluripotent state. Yet the reprog-
rammed cells, when injected into immunodeficient mice,
consistently generate PanIN lesions that can progress to inva-
sive PDAC. We developed conditions for isolating the early-
stage lesions, culturing the cells, and performing proteomic
studies on proteins that are secreted or released and stable.
We discovered known networks and a previously unappreci-
ated network that we find to be associated with early to inva-
sive stages of pancreatic cancer. These studies provide an
example of where a rare iPSC line can be validated against
known features of human cancer and provide potential bio-
markers and insights into networks activated in early to inter-
mediate stages of the disease.
RESULTS
Creating iPSC-like Lines from Human Pancreatic Ductal
Adenocarcinoma
We obtained human pancreatic ductal adenocarcinoma
samples immediately after resection (Table S1). Histologically
normal pancreatic tissues at the margin of the specimens
were used as controls. Epithelial cells were isolated and
cultured in serum-free medium with cholera toxin, to impair
the growth of fibroblasts. We performed two successive infec-
tions of the pancreatic cancer and margin cells with five
lentiviruses separately encoding doxycycline-inducible mouse
Oct4, Sox2, Klf4, and c-Myc and the rt-TA transactivator,Cwhile isolating genomic DNA from the pancreatic specimen
margin and cancer epithelial cells that had been cultured
separately. Pyrosequencing analysis revealed KRAS mutant
cells in seven of nine of the initial tumor samples (Tables S1
and S2). Embryonic stem cell (ESC)-like colonies began to
arise after 7 days, with fewer colonies arising from cancer
epithelial cells. ESC-like clones from cancer or margins started
to differentiate and disappear 4 days after withdrawal of
doxycycline. Thus, we maintained colonies in the presence of
a low doxycycline concentration (50 ng/ml) and called the
resulting lines ‘‘iPSC-like’’ because of their dependency upon
doxycycline. We established iPSC-like lines from four of
the nine tumor epithelial specimens and corresponding margin
iPSC-like lines from three of the specimens (Figure 1A;
Table S1).
We characterized the cells’ pluripotency by RT-PCR,
immunostaining, embryoid body formation, teratoma assays,
karyotyping, and a subset by CpG methylation analysis. Most
iPSC-like lines expressed endogenous pluripotency marker
RNAs and protein (Figures 1B, 1C, and S1A–S1D). Teratoma
assays in immunodeficient NSG mice and embryoid body
assays revealed that the 10–12 pancreatic margin and 10–22
cancer iPSC-like lines from the tenth patient (Figures 1D, 1E,
and S2A) and the 14–24 pancreatic margin and 14–27 cancer
iPSC-like clones from the 14th patient (Figure S1E and S1F)
could generate tissues of multiple germ layers, demonstrating
pluripotency. The original tumor 10 was negative for NANOG
expression and exhibited sporadic expression of POU5F1/
OCT4 (Figure S2B). Detailed pyrosequencing analysis of
CpG methylation showed that the 10–22 iPSC-like line ex-
hibited demethylation at nine of nine sites at the NANOG pro-
moter, compared to the primary tumor and at three of six sites
at the OCT4 promoter; by comparison, the H1 huES line was
similarly demethylated at NANOG and demethylated at four
of six sites at POU5F1 (Figure S2C). Thus, the iPSC-like lines
exhibit diverse characteristics of reprogrammed pluripotent
cells.
We screened all iPSC-like lines for mutations in KRAS,
CDKN2A, and BRAF, which are common genetic alterations in
pancreatic cancer (Moskaluk et al., 1997) (Tables S2 and S3).
The 10–22 iPSC-like line, derived from the recurrent, invasive,
and poorly differentiated PDAC of the tenth patient, harbors
the same KRASG12Dmutation seen in the initial tumor epithelial
population (Figure 1F; Tables S1 and S2). A total of 10–22
cells also possess a CDKN2A heterozygous deletion (Fig-
ure 1H; Table S2) and a comparative genomic hybridization
(CGH) pattern with numerous chromosomal aberrations, more
exaggerated than that of the primary cancer culture and a corre-
spondingly aberrant karyotype (Figure 1I and S3). The exagger-
ation of the primary cancer CGH pattern in the 10–22 iPSC-like
line is expected because the primary cancer culture contained
some stromal cells and thus was contaminated by cells of a
normal genotype. Specifically, we detected 23 gross chromo-
somal aberrations in the PDAC epithelial cell population of the
tenth tumor and 20 were represented in the 10–22 line (Figures
1I and S3B). Decreased CGH signals in the primary tumor cells
and the 10–22 line spanned PTEN and DPC4 (SMAD4), consis-
tent with observations of allelic loss of these loci in humanell Reports 3, 2088–2099, June 27, 2013 ª2013 The Authors 2089
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Figure 1. Establishing iPSC-like Lines from Patient-Matched Margin and Pancreatic Ductal Adenocarcinoma
(A) Cells from pancreatic cancer and margin tissues were reprogrammed and different passages of the 10–12 margin and 10–22 cancer iPSC-like clones from
patient 10 are shown.
(B and C) Expression of pluripotency markers in 10–12 margin and 10–22 cancer iPSC-like lines by immunostaining (B) and RT-PCR (C).
(D) Three month teratomas in NSG mice from 10–12 margin and 10–22 cancer iPSC-like lines showed differentiation into tissues of all three germ layer lineages.
See also Figure S2A.
(E) Expression of differentiationmarkers for endoderm (CXCR4), mesoderm (RUNX1), and ectoderm (SOX1,PAX6) relative toGAPDH in embryoid bodies fromH1
huES cells and 10–12 margin and 10–22 cancer iPSC-like lines cultured for 12–14 days. Error bars represent mean ± SD.
(F and G) DNA sequence tracks revealing KRASmutation and karyotype showing subtetraploidy in the 10–22 cancer iPSC-like line (F) and wild-type KRAS and
normal karyotype in the 10–12 margin iPSC-like line (G).
(H) PCR analysis of CDKN2A (p16Ink4a) exon 2 reveals a heterozygous deletion in 10–22 cells.
(I) Comparative genomic hybridization showing normal profiles for the tenth primary margin cells (orange) and the 10–12 margin iPSC-like line (blue). Gross
chromosomal rearrangements are evident in the tenth primary cancer cell culture (green), which was mixed with normal stromal cells; the rearrangements are
(legend continued on next page)
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Figure 2. The 10-22 iPSC-like Cells Prefer-
entially Generate Ductal Structures in Tera-
tomas
(A) Summaries of teratoma tissue types arising in
3 months in immunodeficient mice based on the
number of histologic structures seen. Teratomas
from huES cells are mostly ectodermal in
appearance, whereas teratomas from 10–12 and
10–22 iPSC-like lines are mostly endodermal/
ductal.
(B) Hematoxylin and eosin staining of the margin
and tumor tissue of patient 10 and of teratomas
formed by 10–12 margin and 10–22 cancer iPSC-
like lines after 3 months. The latter lines create
tubular, duct-like structures independent of
passage number. Notably, the 10–22 cancer
teratomas show a much a higher degree of dif-
ferentiation than the primary tumor.
(C) The primary tumor shows an invasive pheno-
type (dotted line) and high nuclear to cytoplasmic
ratio (arrow).
(D) 10–22 tumor iPSC teratomas at 3 months show
a low nuclear to cytoplasmic ratio, intracellular
mucins (arrows), and a more differentiated
phenotype.
See also Tables S1, S2, and S3.pancreatic cancers (Hahn et al., 1995, 1996). By contrast, the
isogenic 10–12 pancreatic margin iPSC-like line had wild-type
KRAS, a flat CGH chromosomal profile, similar to the parental
margin cell culture and a normal karyotype (Figures 1G–1I and
S3; Table S2). We conclude that the 10–12 and 10–22 iPSC-
like lines are derived from pancreatic margin and cancer epithe-
lial cells, respectively, with the 10–22 line harboring the marked
genomic rearrangements seen in the initial advanced tumor
epithelial population.
The iPSC-like lines from the 14th patient (Figure S1A and S1B),
with moderately differentiated PDAC containing scattered 1 mm
foci, showed point mutations in CDKN2A and BRAF but a wild-
type KRAS, as with the parental epithelial culture (Tables S1
and S2), and flat CGH profiles (data not shown). A pair of margin-
and cancer-derived iPSC-like lines from the 19th patient (Figures
S1C and S1D) also had somaticmutations inCDKN2A, with wild-
type KRAS and BRAF (Table S2). Because the 10–22 cancer
iPSC-like line from the tenth patient contained the KRASmutant
background, typical of PDAC, we performed a detailed study of
that line and its isogenic 10–12, KRAS wild-type margin iPSC-
like clone.evident more clearly in the 10–22 cancer iPSC-like line (red) (see also Figure S3B), demonstrating that th
the initial tumor epithelial cell population. The locations of PTEN and DPC4 (SMAD4) loci are shown in reg
10–22 cells.
See also Tables S1, S2, and S3.
Cell Reports 3, 2088–20910–22 iPSC-like Cells from
Advanced Human PDAC, upon
Differentiation, Undergo the Early
Stages of Pancreatic Cancer
Despite being derived from cancer, the
10–22 cancer iPSC-like line as well as itscompanion 10–12 margin line gave rise to much smaller subcu-
taneous teratomas, at 3 months, compared to those seen from
the control H1 human ESCs. More striking, there was a much
higher proportion of endodermal, Dolichos biflorus agglutinin
(DBA) lectin-positive ductal structures in teratomas from the
10–12 and 10–22 iPSC-like lines (Figures 2A and S4A), whereas
H1 cells generated mostly neuronal lineages, as seen previously
(Bock et al., 2011). These results are in concordance with reports
on the propensity of other iPSC lines to differentiate into the line-
age from which they were derived (Bar-Nur et al., 2011; Kim
et al., 2011).
We next compared the endodermal teratomas arising from the
margin (10–12) and tumor (10–22) iPSC lines with the original
tumor of the tenth patient. The original tumor exhibited many
areas of poorly differentiated foci and infiltration, although occa-
sionally showed a more organized epithelium, but no PanINs
(Figures 2B, 2C and S4B). The tumor epithelium exhibited irreg-
ularly shaped and hyperchromatic nuclei and a high nuclear to
cytoplasmic ratio (Figure 2C, arrow), along with cytoplasmic pro-
trusions indicative of an invasive phenotype (dotted line in Fig-
ure 2C). By contrast, teratoma ductal tissues at 3 months frome 10–22 line is clonally derived representative of
ions of chromosome loss in the tenth cancer and
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Figure 3. Teratomas at 3 Months from 10–22 Cancer iPSC-like Cells
Exhibit PanIN-like Structures and Marker Expression
(A–C) No K19 staining in mouse subcutaneous tissue (negative control), weak
K19 staining of 10–12margin iPSC-like teratomas at 3months, and strong K19
staining of 10–22 cancer iPSC-like teratomas at 3 months.
(D–I) Nuclear staining of PDX1 (arrow) and cytoplasmic staining of MUC5AC
(arrow) only in teratomas of 10–22 cancer iPSC-like teratomas at 3 months.
(J and K) Higher magnification shows uniformK19 staining (J and J0, arrow) and
heterogeneous MUC5AC staining (K and K0) of teratomas from 10–22 cancer
iPSC-like cells.
See also Tables S1, S2, and S3.the 10-22 cancer iPSC-like line had a high level of architectural
organization, with abundant gland formation and a more differ-
entiated cytology compared to the primary tumor (Figure 2B).
This included an increased cytoplasm and smaller, less hyper-
chromatic nuclei with even nuclear membrane contours, a
decreased nuclear to cytoplasmic ratio and increased cell polar-
ity, indicative of PanIN stages. Abundant mucin was present in
the apical aspect of the cells (arrows in Figure 2D). There was
no evidence of acinar differentiation or neuroendocrine
neoplasia. PanINs are graded by the extent of dysmorphic struc-
tures compared to normal ducts (Hruban et al., 2001) and we
observed a range of PanIN1-, PanIN2-, and PanIN3-like struc-
tures in the histology of the endodermal teratomas from the
10–22 iPSC-like line at 3 months; although predominantly struc-
tures resembling the PanIN2 and PanIN3 stages (Figures S4C–2092 Cell Reports 3, 2088–2099, June 27, 2013 ª2013 The AuthorsS4G). Taken together, these findings suggested that the 10–22
cancer iPSC-like line generates ductal structures that resemble
PanIN (Maitra and Hruban, 2008).
PanIN-like teratomas formed in nine of ten teratoma experi-
ments at 3 months, regardless of the passage number of the
10–22 cells. By contrast, the 10–12 pancreatic margin iPSC-
like line did not generate PanIN-like structures in teratomas
(n = 4) (Figure 2B). Also, iPSC-like lines from the 14th and 19th
tumors, containing predisposing mutations, but not of KRAS,
did not generate PanIN-like lesions (n = 5, data not shown) and
therefore were not studied further.
PCR of DNA obtained by laser capture microdissection
showed that the stromal cells surrounding the ductal epithelium
in the PanIN-like teratomas of the 10–22 line contained the rt-TA
lentiviral DNA and thus were derived from the starting 10–22 cells
(Figure S4H). This was confirmed by detecting rT-TA expression
in the PanIN-like epithelium as well as throughout the local
stroma, but not in the distal stromal portions of subcutaneous
tissue (Figure S4I). Recently, stromal-like cells surrounding
PDAC have been found to be derived by EMT from the pancre-
atic cancer epithelium in a mouse model (Rhim et al., 2012).
However, the study observed very few EMT-derived stromal
cells at the PanIN stages. Taken together, it seems that most
but perhaps not all of the human stromal cells in the PanIN
regions of the teratomas were derived by local codifferentiation
of the pluripotent 10–22 cells into epithelial and mesenchymal
tissues.
Characterizing the ductal structures in teratomas of the 10–22
cancer iPSC-like line in further detail, we found that they
expressed keratin 19 (K19) as well as nuclear PDX1, the pancre-
atic determination factor, and nuclear SOX9 (Figures 3A–3F, 3J,
and S5A–S5E). PDX1 is expressed at very low levels in adult
pancreatic duct cells, it is not expressed in adult exocrine cells,
and it is upregulated in pancreatitis, PanIN, and PDAC (Miyat-
suka et al., 2006). SOX9 is a coordinate effector, with mutant
Kras, of precursor pancreatic lesions in a mouse model (Kopp
et al., 2012). Teratomas from the 10–12 pancreatic margin
iPSC-like cells did not express the gastric mucin MUC5AC,
whereas the PanIN-like structures of the teratomas from the
10–22 cells expressed abundant MUC5AC (Figures 3G–3I, 3K,
brown staining, and S5A), as observed in PanIN lesions and
well-differentiated PDAC (Kim et al., 2002). Considering the
histology and CGH genomic profile of the parental pancreatic
cancer tissue from which the 10–22 iPSC-like line was derived,
the data indicate that the 10–22 iPSC-like line from poorly differ-
entiated, late-stage PDAC can differentiate into PanIN lesions
associated with the early stage of the disease.
The 10-22 iPSC-like Line PDAC Progresses to the
Invasive Stage of Human Pancreatic Cancer
To assess whether PanIN-like structures from the 10–22 line
could progress to later stages of PDAC, we investigated tera-
tomas grown for 6–9 months in NSG mice. By 9 months, two
solid, palpable tumors arose in each of two injected mice
(3–6 mm diameter), all with a genotype characteristic of 10–22
cells (Figure S5F). Although palpable tumors were not evident
at 6 months, histological analysis showed highly glandular struc-
tures with nuclear heterotypia and hypochromia at both 6 and
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Figure 4. Teratomas at 6 and 9 Months
from 10–22 Cancer iPSC-like Cells Exhibit
Invasive Stages of Pancreatic Cancer
(A and B) Hematoxylin and eosin staining of 10–22
teratomas in NSG mice at 6 months (A and A0 ) and
9months (B andB0 ). Arrows indicate epithelial cells
with a more dysmorphic phenotype than at
3 months; nuclei are heterotypic and epithelia with
hypochromic nuclei are invading the stroma (A and
B, arrows).
(C–R) Immunohistochemistry showing epithelial
cells positive for K19, MUC5AC, PDX1, and SOX9
in tumors arising at 6 and 9 months in NSG
mice injected with 10–22 cells. See Figure S5F for
genetic confirmation of 10–22 cells in the tumors.
See also Tables S1, S2, and S3.9 months (Figures 4A and 4B). The epithelial cells were positive
for K19, MUC5AC, PDX1, and SOX9 (Figures 4C–4R, arrows).
Notably, we observed structures indicative of a locally invasive
phenotype (Figures 4A and 4B, arrows). We conclude that the
PanIN-like stage of teratomas from the 10–22 iPSC-like line is
succeeded in vivo by the invasive stage of PDAC, indicating
that the 10–22 iPSC-like model undergoes a spectrum of
pancreatic carcinogenesis.
Cultured Organoids of PanIN-like Cells from 10–22 Line
Teratomas Secrete or Release Proteins Indicative of
Early-Stage Pancreatic Cancer
We sought to generate a system where the PanIN-like structures
occurring within teratomas from the 10–22 cells could be studied
as a live, in vitro model of early-stage human pancreatic cancer.
Accordingly, we harvested tissues from teratomas 3 months
after injection, along with contralateral control tissue and estab-
lished conditions where the tissues were embedded separately
into Matrigel and cultured in vitro (Figure S6A). PCR analysis of
DNA from the resulting sphere-like organoids confirmed theCell Reports 3, 2088–20910–22 line genotype, which was absent
from contralateral control explants (Fig-
ure S6B). The organoids from the 10–22
cancer iPSC-like cells retained the
expression of human K19 and MUC5AC
(Figures 5A–5C, sections).
Given the poor prognosis of PDAC, we
used the organoid system to identify
biomarkers and pathways that could
permit early detection and facilitate dis-
ease monitoring after therapy. We used
nanoLC/MS/MS to examine the proteins
that were secreted or released from
explants of three independent teratomas
that were cultured for 6 days (Figure 5D,
left). The data were compared to proteins
secreted or released from explants of
contralateral control tissue cultured simi-
larly and from the parent 10–22 iPSC-
like line cultured in the undifferentiated
state. We then selected peptides withperfect matches to human peptides and that were specific to
the human PanIN-like teratoma explants (Figure 5D, right). Of
the 25 proteins that were secreted or released from all three
10–22 teratoma explants (Figure 5D, right; Table S4), eight
were previously reported to be expressed at the RNA or protein
levels within PanIN, IPMN, and/or PDAC, whereas the remaining
proteins have not been reported (Harsha et al., 2009) (Table S5).
Of the 82 proteins that were identified from the intersection of
pairs of 10–22 teratoma explants (Figure 5D, right; Tables S6,
S7, and S8), 15 proteins have been previously reported in
PanIN/IPMN/PDAC (Harsha et al., 2009) (Table S5). Although
certain mRNAs were previously identified in PanIN, such as
PGAM-M and VWF (Buchholz et al., 2005), we have determined
that the corresponding proteins are secreted or released from
cells and remain stable in the medium.
Of the total 107 proteins secreted or released from at least two
10–22 teratoma explants, Ingenuity pathway analysis revealed
that 42 fall into interconnected TGFb1 and integrin signaling net-
works (Figure 5E, for 38 proteins). These pathways have been
previously reported in PanIN, IPMN, and PDAC (Bardeesy9, June 27, 2013 ª2013 The Authors 2093
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Figure 5. Proteins Secreted and HNF4 Reg-
ulatory Network within Teratoma Explants
of 10–22 iPSC-like Cells at 3 Months
Scheme for in vitro explants of 3 month teratomas
from 10–22 cancer iPSC-like lines.
(A–C) Whole mount view of teratoma explant from
10–22 iPSC-like cells (A), along with the explant
sectioned and stained for K19 (B), and MUC5AC
(C); arrows indicate positive (brown) domains.
(D) Proteomic analysis of conditioned media of 3
independent teratoma explants (7761, 9223, and
9225) from 10–22 cancer iPSC-like cells. Condi-
tioned media was analyzed by nanoLC/MS/MS
and protein candidates were identified by a
Sequest search in the International Protein Index
database. Using UniProKB TrEMBL (downloaded
in October, 2011), we included peptides in our list
that either consists of uniquely human sequences
or sequences that are common to humans and
mice. Mouse-specific sequences were excluded.
Protein identifications of conditioned media from
teratoma explants were compared to those in
conditioned media from explants of contralateral
control tissue and of media from undifferentiated
10–22 ells (left Venn diagram). The total 698
secreted or released proteins specific to the tera-
tomas are indicated in the three different experi-
ments (right Venn diagram). Proteins secreted
from at least two teratoma explants (red numbers)
are summarized in Table S4 and were used for
pathway analysis.
(E) Numerous proteins fall into linked pathways for
TGFb and integrin signaling. Lines and arrows
connecting molecules indicate direct interactions
and dashed lines and arrows indicate indirect
interactions.
(F) All proteins in red are secreted or released specifically from the 10–22 teratoma explants and fall within a network controlled by the transcription
factor HNF4a (Table S4). Asterisks denote proteins whose genes are directly bound by HNF4a.
See also Tables S5, S6, S7, S8, and S9.et al., 2006; Jones et al., 2008). In summary, we discovered
numerous proteins that are secreted or released from the 10–
22 live cell model of early-stage human pancreatic cancer, as
well as evidence of well-documented pathways involved in early
cancer progression.
HNF4a Network Activated in Early- to Intermediate-
Stage, but Not Late-Stage, Pancreatic Cancer
Further Ingenuity analysis revealed that another 25 of the
secreted or released proteins were in a network that we
observed to be centered on the transcription factor HNF4a,
including numerous direct gene targets (Odom et al., 2004) (Fig-
ure 5F; Table S9). Nine of the proteins in theHNF4a networkwere
also secreted into the plasma during the PanIN stage of a mouse
PDAC model (Table S9) (Taguchi et al., 2011). Although HNF4a
has not been reported in the development or progression
of PDAC, by searching databases, we noted the amplification
of the HNF4a locus (Maser et al., 2007) and the upregulation of
HNF4a mRNA (Iacobuzio-Donahue et al., 2003; Logsdon et al.,
2003) in human PDAC. Although some reports show HNF4a in
pancreatic acinar cells as well as islets in adult mice (Gupta
et al., 2007), we found HNF4a to be predominantly expressed
in islets, with very low or no expression elsewhere in the normal2094 Cell Reports 3, 2088–2099, June 27, 2013 ª2013 The Authorspancreas (Figure S6C). Strikingly, although HNF4a was not
expressed in normal human or mouse pancreatic ducts (Figures
6A and S6C), it was expressed in the nucleus of 10–22 teratoma
PanIN-like cells at 3months and invasive-stage cells at 9months
(Figures 6B, 6C, and S6D). HNF4awas detected cytoplasmically
in moderately differentiated domains of the original tumor of the
tenth patient, from which 10–22 cells were derived, but not in
undifferentiated portions of the tumor (Figure 6D).
To more quantitatively assess HNF4a expression at different
stages of human pancreatic cancer, we used a tissue microarray
to assess multiple samples of human PanINs at different stages
as well as samples of pancreatic cancer. HNF4a was barely
detected in the nuclei of normal pancreatic ducts and very
weakly in the samples of PanIN-1 cells, but exhibited a statisti-
cally significant increase in nuclear expression in the samples
of PanIN-2 (p < 0.05) and stronger and more uniform expres-
sion in PanIN-3 epithelia (p < 0.05) (Figures 6E–6G, and 6J;
Table S10). HNF4a was most frequently detected in well-differ-
entiated mucinous sections of PDAC (p < 0.01) and barely or
not detectable in undifferentiated or poorly differentiated epithe-
lial structures of PDAC (Figures 6H–6J), as seen in the original
patient 10 tumor (Figure 6D). We also note that in the human
protein atlas (Uhlen et al., 2010), HNF4a appeared positive
in well-differentiated epithelial structures of PDAC but either
cytoplasmic or not expressed in poorly differentiated or undif-
ferentiated epithelial structures of PDAC and not expressed in
metastatic PDAC.
We assessed HNF4a in a mouse model of PDAC arising in
a KrasG12D;p53L/+; Pdx1-Cre; RosaLSL-YFP background (Rhim
et al., 2012). As in humans, HNF4a was sporadically expressed
at the PanIN-1 stage (Figure 6K), it was expressed in most nuclei
of PanIN-2 (Figure 6L) and PanIN-3 lesions (Figure 6M) and
observed in nuclei of the more differentiated portions of the
murine tumors but not in the undifferentiated portions (Figures
6N and 6O, white arrows). In conclusion, we validated the ability
of the 10–22 iPSC-like cells to undergo early stages of human
pancreatic cancer by their morphology, histology, secreted, or
released proteins, and using them to discover a previously unap-
preciated network associated with early to invasive-stage
pathology in human clinical samples and a mouse model of the
disease.
DISCUSSION
There has been an absence of live human cell models of PDAC
progression and consequently little information about proteins
that could serve as released biomarkers and pathway indicators
for early stages of the disease. As noted in the Introduction,
when human PDAC or pancreatic cancer stem cells are grafted
into immunodeficient mice, tumors rapidly arise that resemble
the advanced PDAC stages from which the cells were derived
and they do not undergo the slow growing phenotype of
PDAC precursors. We hypothesized that, based on the ability
of certain cancer cells to be reprogrammed to pluripotency by
nuclear transfer and then to undergo early mammalian develop-
ment, pluripotent stem cell lines from human pancreatic tumors
might have the capacity to progress through early develop-
mental stages of the cancer. This would provide an opportunity
for discovering intrinsic processes and secreted protein
biomarkers of live, early-stage human cells for a devastating
cancer. Indeed we showed that a rare, single pancreatic cancer
iPSC-like line, 10–22 cells, can provide insights into human
cancer progression.
How does the ectopic expression of Oct4, Sox2, Klf4, and
c-Myc and a pluripotent-like state suppress the cancer pheno-
type? Apparently the pluripotency epigenetic environment can
dominate over certain oncogenic states (Esteller, 2007). In
nuclear transfer studies, only certain cancer cells are amenable
to reprogramming (Blelloch et al., 2004; Hochedlinger et al.,
2004; Li et al., 2003) and, similarly, we only obtained one iPSC-
like line from pancreatic cancer harboring a KRAS mutation,
the predominant driver of PDAC. Although theKRASmutation in-
duces MAPK signaling, which can trigger mouse ESCs to differ-
entiate (Kunath et al., 2007), in human ESCs,MAPK signaling can
promote self-renewal (Eiselleova et al., 2009). Oncogenic RAS
induces cellular senescence by the accumulation of p53 or
CDKN2A (Serrano et al., 1997) and the expression of the four
reprogramming factors also triggers senescence by inducing
p53 and CDKN2A, thereby impairing reprogramming (Banito
et al., 2009). Only patient 10 in our study had a deletion in
exon2 of CDKN2A, possibly explaining how the 10–22 cellsCcould escape a senescent phenotype. Additional mutations
could have arisen in the 10–22 cells that made the cells particu-
larly amenable to iPSC formation. Further work will determine
what kind of mutations predict whether a cancer cell can be
reprogrammed to pluripotency.
How does release from pluripotency allow the cancer genome
to be expressed in a stage-specific fashion, as opposed to un-
dergoing an immediate regression to the late-stage phenotype?
Although the answers to these questions are not in hand, release
from pluripotency is normally accompanied by the development
of germ layer cells and then specialized tissues, which may
continue to dominate, epigenetically, over the resident cancer
genome (Blelloch et al., 2004; Hochedlinger et al., 2004; Li
et al., 2003). The 10–22 cells from PDAC generated diverse tis-
sue types in teratomas as well as pancreatic ductal tissue that
exhibited PanIN lesions and later progression. The apparent
preference for pluripotent cells to regenerate the cancer type
from which they were derived reflects the tendency of iPSC lines
in general to preferentially differentiate into their lineages of
origin (Bar-Nur et al., 2011; Kim et al., 2011).
Several lines of evidence indicate that the 10–22 iPSC-like line
is derived from PDAC. First, the pathology of the original, recur-
rent tumor was that of PDAC and the CGH profile of the bulk
population of cultured cells, which had a highly disrupted
genome, was represented in the CGH profile of the 10–22
iPSC-like line (Figures 1I and S3B). Although the tumor harbored
pockets of more differentiated epithelial cells amidst a vast
majority of undifferentiated cells, and therefore it is not certain
which type of cell was immortalized in the 10–22 line, the
10–22 cells’ disrupted genome does reflect that of a typical
epithelial cell in the recurrent tumor. Second, the PanIN-like
structures from the 10–22 cells’ teratomas expressed SOX9
(Figures S5B–S5E), which is required for early, KrasG12D-depen-
dent pancreatic precursor lesions in a mouse model (Kopp et al.,
2012), as well as PDX1, a definitive pancreatic cancer epithelial
marker. Thus the ductal lesions from the 10–22 cells are of a
pancreatic type. Third, teratomas at 9 months from 10–22 cells
progressed to the histology and locally invasive characteristics
of later-stage PDAC (Figure 4). Thus, the 10–22 line was not
from an early-stage cell that would solely undergo an early-
stage phenotype. Taken together, the evidence indicates that
the 10–22 iPSC-like line is from PDAC cells in the original tumor
and that, upon redifferentiation in teratomas, it undergoes pro-
gression of the disease. This is unlike other human PDAC lines,
which exhibit late stages of cancer (Lieber et al., 1975; Yunis
et al., 1977).
Could the 10–22 iPSC-like line be derived from cancer stem
cells within the original tumor? Pluripotency genes such as
NANOG are expressed in sphere cultures of pancreatic cancer
stem cells (CSCs), suggesting that such cells might bemore sus-
ceptible to reprogramming (Lonardo et al., 2011). However,
CD133+CXCR4+ pancreatic CSCs are not enriched and the
expression of pluripotent genes is not observed in the adherent
culture conditions we used to derive the 10–22 cells (Hermann
et al., 2007). Also, the OCT4 and NANOG pluripotency genes
were highly methylated in the parental tumor 10 epithelium cul-
tures, in contrast to the 10–22 cell line and the huES H1 control,
and NANOG itself was not expressed in the primary tumor,ell Reports 3, 2088–2099, June 27, 2013 ª2013 The Authors 2095
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Figure 6. Activation ofHNF4a in PanINCells andWell-Differentiated Early Pancreatic Cancers in HumanClinical Samples and aMouseModel
of Human PDAC
(A–D) Immunohistochemistry for HNF4a showing the absence of staining in the main human pancreatic mass and ducts (A), strong nuclear staining in PanIN-like
structures in a 3 month teratoma (B, arrow) and in invasive cells in a 9 month tumor (C, arrow) generated from NSG mice injected with 10–22 cells, and mostly
(legend continued on next page)
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although OCT4 was expressed sporadically (Figures S2B and
S2C). Taken together, it seems unlikely that 10–22 cells were
derived from pancreatic CSCs. In addition, pancreatic CSCs
(Hermann et al., 2007; Ishizawa et al., 2010; Li et al., 2007) rapidly
generate aggressive tumors that represent the primary tumors;
whereas the 10–22 cells generate slow growing PanINs (Figures
3 and S4). Finally, tumors generated with pancreatic CSCs give
rise to both cytokeratin negative and positive cells in the resul-
tant tumors, in contrast to the homogenous K19 positive staining
in PanIN-like ducts at 3 month teratomas (Figures 3 and S2A).
Thus, 10–22 cells appear not to exhibit properties of pancreatic
cancer stem cells.
The proteins released or secreted from the PanIN-like tera-
tomas fell into three major networks, including interconnected
networks for TGFb and integrin signaling that suppress PDAC
progression (Hezel et al., 2012). We also report the activation
of an HNF4a network distinctive for the late PanIN stages.
HNF4a is not or barely expressed in normal pancreatic ductal
cells, poorly expressed in the PanIN1 stage, but is activated in
PanIN2 and PanIN3 stages, invasive stages, and in early well-
differentiated human pancreatic cancer. HNF4a levels then
decrease markedly in advanced or undifferentiated PDAC. We
found that these expression states also occur in a mouse model
of PDAC progression. Dynamics in HNF4a expression affect the
oncogenic transformation of liver cells (Hatziapostolou et al.,
2011). It remains to be determined whether the expression of
HNF4a and its target genes is a cause or consequence of
pancreatic cancer progression. Yet considering that pancreatic
cancer is typically discovered in advanced or metastatic stages,
activation of HNF4a and the release or secretion of proteins from
the factor’s target genes specifically in the late PanIN stages
should provide useful diagnostics.
Of 107 proteins reproducibly released or secreted from
PanIN-like cells derived from the 10–22 line, a total of 68 pro-
teins overlap with genes, proteins, and networks expressed in
human PanIN and PDAC, further validating the origin of the cells.
In addition, we show that such proteins are released from
the cells and stable, thus serving as potential biomarkers of
early PDAC. A subset of the secreted proteins could be from
locally activated stromal cells in the explants. We suggest that
the combined detection of released proteins that are the
products of the HNF4a, TGFb, and integrin networks within
PanIN and invasive PDAC cells may provide the best means
for noninvasively detecting the progression of pancreatic cancer
in humans.
Based on our extensive efforts with diverse initial PDAC
samples (see Tables S1 and S2), iPSCs arising from epithelialcytoplasmic staining in small, moderately differentiated ducts (D, image sectio
undifferentiated ducts (D, image section above the diagonal) of the tenth patient
(E–I) HNF4a is weakly labeled in human PanIN-1 cells (E, arrow, n = 8), stro
well-differentiated human PDAC (H, arrow, n = 8) but decreased or not in undiffe
(J) Percentage of HNF4a positive nuclei to total nuclei counted (see Table S4) in
represent SEM. The differences in HNF4a expression is statistically significan
well-differentiated PDAC (**p = 5.46E-06); well-differentiated PDAC and poorly/u
(K–O) In a mouse model of PDAC, HNF4a is expressed weakly at the PanIN1 (K a
portions of tumors (PDAC) (N and N0 ), and weakly or not expressed in undifferen
See also Table S10.
Ccells of solid tumors appear to be rare events, possibly
involving secondary changes that allow iPSC formation. It is
therefore unclear whether the iPSC approach will work with
other solid tumor samples. Despite these caveats, the 10–22
cells behaved in a highly consistent fashion, and this study re-
vealed information about human PDAC. It is hoped that a better
understanding of how to create iPSCs from human epithelial
cancers will provide opportunities in the future with other types
of solid tumors.
EXPERIMENTAL PROCEDURES
Tissue (1–2 cc) was taken from the center of pancreatic ductal adenocarci-
noma samples and sample margin furthest from the cancers, under the
patient’s informed consent under IRB 09-801 at the Fox Chase Cancer Center.
Tissue was dissociated and cells were cultured in defined K-SFM supple-
mented with EGF, cholera toxin, and bovine pituitary extract on dishes coated
with collagen at 37C for 3–4 days. The resultant epithelial cells were infected
twice with TetO mouse Oct4, Sox2, Klf4, and c-Myc and PWPT-rtTA lentivi-
ruses for 72 hr. Approximately 105 cells surviving per starting tumor or margin
tissuewere detached, resuspended in ESCmedia supplementedwith Y27632,
and plated onto irradiated mouse embryonic fibroblasts (MEFs). ESC-like col-
onies were picked 12–36 days postinfection and passagedmechanically every
5–7 days onto irradiated MEFs, with daily feedings. The iPSC-like lines were
characterized by RT-PCR and immunostaining for pluripotency markers,
embryoid body and teratoma assays for pluripotency, and CGH, karyotyping,
PCR for KRAS,CDKN2A, andBRAFmutations, and pyrosequencing for KRAS
mutations. Female 4–6-week-old NOD-SCID-IL2Rgc null (NSG) mice (Shultz
et al., 2005) were used for subcutaneous injection of the iPSC-like lines. The
injection area was isolated after 3–9 months and analyzed by histology or
dissociated in liberase T-flex (1.3W/ml), embedded into Matrigel, and cultured
in SFM. Conditioned media was collected and proteins were processed for
analysis by nanoLC/MS/MS. See the Extended Experimental Procedures for
details.
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